Přejít k obsahu
Merck

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity.

Nature biotechnology (2008-07-01)
Ofra Benny, Ofer Fainaru, Avner Adini, Flavia Cassiola, Lauren Bazinet, Irit Adini, Elke Pravda, Yaakov Nahmias, Samir Koirala, Gabriel Corfas, Robert J D'Amato, Judah Folkman
ANOTACE

Targeting angiogenesis, the formation of blood vessels, is an important modality for cancer therapy. TNP-470, a fumagillin analog, is among the most potent and broad-spectrum angiogenesis inhibitors. However, a major clinical limitation is its poor oral availability and short half-life, necessitating frequent, continuous parenteral administration. We have addressed these issues and report an oral formulation of TNP-470, named Lodamin. TNP-470 was conjugated to monomethoxy-polyethylene glycol-polylactic acid to form nanopolymeric micelles. This conjugate can be absorbed by the intestine and selectively accumulates in tumors. Lodamin significantly inhibits tumor growth, without causing neurological impairment in tumor-bearing mice. Using the oral route of administration, it first reaches the liver, making it especially efficient in preventing the development of liver metastasis in mice. We show that Lodamin is an oral nontoxic antiangiogenic drug that can be chronically administered for cancer therapy or metastasis prevention.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
Ethylenediamine, ReagentPlus®, ≥99%
Sigma-Aldrich
Ethylenediamine, purified by redistillation, ≥99.5%
Sigma-Aldrich
Coumarin 6, 98%
Supelco
Ethylenediamine, analytical standard
Sigma-Aldrich
Ethylenediamine, BioXtra
Sigma-Aldrich
Ethylenediamine, meets USP testing specifications
Sigma-Aldrich
Ethylenediamine, puriss. p.a., absolute, ≥99.5% (GC)
Sigma-Aldrich
Coumarin 6, ≥99%